Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.

How to buy Glaukos Corporation stock | $67.28

Own Glaukos Corporation stock in just a few minutes.

Fact checked

Glaukos Corporation is a medical instruments & supplies business based in the US. Glaukos Corporation shares (GKOS) are listed on the NYSE and all prices are listed in US Dollars. Glaukos Corporation employs 600 staff and has a trailing 12-month revenue of around USD$217.6 million.

How to buy shares in Glaukos Corporation

  1. Compare share trading platforms. If you're a beginner, look for a platform with low commissions, expert ratings and investment tools to track your portfolio. Narrow down top brands with our comparison table.
  2. Open and fund your brokerage account. Complete an application with your personal and financial details, like your ID and bank information. Fund your account with a bank transfer, credit card or debit card.
  3. Search for Glaukos Corporation. Find the stock by name or ticker symbol: GKOS. Research its history to confirm it's a solid investment against your financial goals.
  4. Purchase now or later. Buy today with a market order or use a limit order to delay your purchase until Glaukos Corporation reaches your desired price. To spread out your purchase, look into dollar-cost averaging, which smooths out buying at consistent intervals and amounts.
  5. Decide on how many to buy. At last close price of USD$67.28, weigh your budget against a diversified portfolio that can minimize risk through the market's ups and downs. You may be able to buy a fractional share of Glaukos Corporation, depending on your broker.
  6. Check in on your investment. Congratulations, you own a part of Glaukos Corporation. Optimize your portfolio by tracking how your stock — and even the business — performs with an eye on the long term. You may be eligible for dividends and shareholder voting rights on directors and management that can affect your stock.

Glaukos Corporation share price

Use our graph to track the performance of GKOS stocks over time.

Glaukos Corporation shares at a glance

Information last updated 2020-12-26.
Latest market closeUSD$67.28
52-week rangeUSD$23.31 - USD$75.735
50-day moving average USD$68.4612
200-day moving average USD$51.353
Wall St. target priceUSD$59.8
PE ratio 107.8649
Dividend yield N/A (0%)
Earnings per share (TTM) USD$0.37

Buy Glaukos Corporation shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
Name Product Stock trade fee Asset types Option trade fee Annual fee
Sofi Invest
Stocks, ETFs, Cryptocurrency
A free way to invest in stocks, ETFs and crypto.
Stocks, Options, ETFs, Cryptocurrency
Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.
$0 for US stocks
Stocks, Options, ETFs
Trade stocks on the US, Hong Kong, Shanghai and Shenzhen markets.
TD Ameritrade
or $25 broker-assisted
$0 + $0.65/contract,
or $25 broker-assisted
TD Ameritrade features $0 commission for online stock, but watch out for high short-term ETF and broker-assisted trading fees.

Compare up to 4 providers

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy Glaukos Corporation stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Glaukos Corporation price performance over time

Historical closes compared with the close of $67.28 from 2020-12-09

1 week (2021-01-11) -12.84%
1 month (2020-12-18) -6.89%
3 months (2020-10-16) 22.68%
6 months (2020-07-17) 70.03%
1 year (2020-01-17) 17.31%
2 years (2019-01-18) 7.34%
3 years (2018-01-18) 135.66%
5 years (2016-01-15) 251.88%

Is Glaukos Corporation under- or over-valued?

Valuing Glaukos Corporation stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Glaukos Corporation's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.

Glaukos Corporation's P/E ratio

Glaukos Corporation's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 108x. In other words, Glaukos Corporation shares trade at around 108x recent earnings.

That's relatively high compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The high P/E ratio could mean that investors are optimistic about the outlook for the shares or simply that they're over-valued.

Glaukos Corporation's PEG ratio

Glaukos Corporation's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 1.64. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.

The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into Glaukos Corporation's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.

Glaukos Corporation financials

Revenue TTM USD$217.6 million
Gross profit TTM USD$202.4 million
Return on assets TTM -7.4%
Return on equity TTM -17.17%
Profit margin -33.61%
Book value $14.758
Market capitalisation USD$3.3 billion

TTM: trailing 12 months

Shorting Glaukos Corporation shares

There are currently 4.6 million Glaukos Corporation shares held short by investors – that's known as Glaukos Corporation's "short interest". This figure is 8.5% down from 5.0 million last month.

There are a few different ways that this level of interest in shorting Glaukos Corporation shares can be evaluated.

Glaukos Corporation's "short interest ratio" (SIR)

Glaukos Corporation's "short interest ratio" (SIR) is the quantity of Glaukos Corporation shares currently shorted divided by the average quantity of Glaukos Corporation shares traded daily (recently around 388025.46689304). Glaukos Corporation's SIR currently stands at 11.78. In other words for every 100,000 Glaukos Corporation shares traded daily on the market, roughly 11780 shares are currently held short.

However Glaukos Corporation's short interest can also be evaluated against the total number of Glaukos Corporation shares, or, against the total number of tradable Glaukos Corporation shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Glaukos Corporation's short interest could be expressed as 0.1% of the outstanding shares (for every 100,000 Glaukos Corporation shares in existence, roughly 100 shares are currently held short) or 0.142% of the tradable shares (for every 100,000 tradable Glaukos Corporation shares, roughly 142 shares are currently held short).

A SIR above 10% would generally be considered pretty high, pointing to a potentially pessimistic outlook for the share price and a discouraging interest in betting against Glaukos Corporation.

Find out more about how you can short Glaukos Corporation stock.

Glaukos Corporation share dividends

We're not expecting Glaukos Corporation to pay a dividend over the next 12 months.

Glaukos Corporation share price volatility

Over the last 12 months, Glaukos Corporation's shares have ranged in value from as little as $23.31 up to $75.735. A popular way to gauge a stock's volatility is its "beta".

GKOS.US volatility(beta: 1.87)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NYSE average) beta is 1, while Glaukos Corporation's is 1.8709. This would suggest that Glaukos Corporation's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).

Glaukos Corporation overview

Glaukos Corporation, an ophthalmic medical technology and pharmaceutical company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent and iStent inject micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma. The company's product pipeline includes iStent Infinite for use as a standalone procedure in patients with refractory glaucoma; iStent SA, a two-stent product that is designed for use as a standalone glaucoma procedure; iDose Travoprost, a targeted injectable implant based on its micro-scale device-platform that is designed to deliver therapeutic levels of medication; and MicroShunt, an ab-externo device for treatment of open-angle glaucoma. The company markets its products through direct sales organization, as well as through distributors in the United States and internationally. Glaukos Corporation was founded in 1998 and is headquartered in San Clemente, California.

Frequently asked questions

More guides on Finder

Ask an Expert

You are about to post a question on

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and Terms of Use.

Questions and responses on are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site